Overview

First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)

Status:
Completed

Trial end date:
2017-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this pivotal, first in man study will be to evaluate safety and efficacy of the novel, microcrystalline paclitaxel coated balloon (mcPCB, PAK, Balton) in the treatment of femoropopliteal artery disease.

Phase:

N/A

Details

Lead Sponsor:

Balton Sp.zo.o.

Collaborators:

American Heart of Poland
American Heart of Poland, Katowice, Poland

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel